Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
VSTM > SEC Filings for VSTM > Form 8-K on 6-Jun-2013All Recent SEC Filings

Show all filings for VERASTEM, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for VERASTEM, INC.


Change in Directors or Principal Officers, Financial Statements and Exhibits

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 4, 2013, Verastem, Inc. (the "Company") appointed Robert Forrester as its Chief Executive Officer, effective July 1, 2013, and in connection with such appointment, the Board of Directors of the Company (the "Board") unanimously voted to increase the size of the Board to 9 members and to elect Mr. Forrester as a director of the Company. Mr. Forrester will continue to serve as President of the Company. In connection with his election as a director, Mr. Forrester and the Company will enter into a letter agreement which provides that, upon the Board's request, Mr. Forrester will resign from the Board if he is no longer serving as the Company's Chief Executive Officer.

Mr. Forrester, 49, has served as the Company's President since January 2013 and as its Chief Operating Officer since March 2011. Prior to joining the Company, Mr. Forrester served as Chief Operating Officer of Forma Therapeutics, Inc. from 2010 until 2011. Previously he served as Interim President and Chief Executive Officer of CombinatoRx, Inc., now Zalicus Inc., from 2009 until 2010 and as its Executive Vice President and Chief Financial Officer from 2004 to 2009. Mr. Forrester served as Senior Vice President, Finance and Corporate Development at Coley Pharmaceuticals Group, Inc. from 2000 to 2003. Mr. Forrester served as a member of the Board of Directors of Myrexis Pharmaceuticals from 2009 until 2013.

In connection with Mr. Forrester's appointment as Chief Executive Officer, the Board appointed Christoph Westphal, M.D., Ph.D., who previously served as the Company's Chief Executive Officer, as its Executive Chairman, effective July 1, 2013.

A copy of the press release announcing these changes is filed as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

See Exhibit Index attached hereto.

  Add VSTM to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for VSTM - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.